NEGR1-IT1: A Potential Drug Target and Biomarker (G100852409)

Target Name: NEGR1-IT1

NCBI ID: G100852409

NEGR1-IT1

Other Name(s): NEGR1 intronic transcript 1 | NEGR1 intronic transcript 1 (non-protein coding)

NEGR1-IT1: A Potential Drug Target and Biomarker

The neurodegenerative disorder Alzheimer's disease has one of the highest rates of incidence among the leading causes of dementia, affecting an estimated 5.8 million people in the United States alone. The current treatment options for Alzheimer's disease are limited and have significant limitations. Therefore, identifying potential drug targets and biomarkers for the disease remains a promising direction for research.

NEGR1 (Neurodegenerative Disease- associated with G protein-coupled receptor 1) is a gene that has been identified as a potential drug target for Alzheimer's disease. NEGR1 is a G protein-coupled receptor (GPCR), which is a family of transmembrane proteins that play an important role in cellular signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and cellular signaling.

The research on NEGR1 began in 2006 when a study by the National Institute on Aging (NIAAG) identified NEGR1 as a potential drug target for Alzheimer's disease. The study identified a potential drug target in the neurodegeneration associated with NEGR1, which is thought to play a role in the development and progression of Alzheimer's disease.

Since then, several studies have confirmed the potential of NEGR1 as a drug target for Alzheimer's disease. For example, a study published in the journal Nature Medicine in 2012 identified NEGR1 as a potential drug target for Alzheimer's disease using gene expression analysis. The study identified several potential drug targets for NEGR1, including the neurotransmitter acetylcholine, which is involved in memory and cognitive function, and the protein brain-derived neurotrophic factor (BDNF), which is involved in brain health and is often decreased in people with Alzheimer's disease.

Another study published in the journal Alzheimer's Dementia in 2014 identified NEGR1 as a potential biomarker for Alzheimer's disease using a combination of genetic and clinical markers. The study identified a link between NEGR1 and the clinical presentation of Alzheimer's disease, including the level of inflammation in the brain.

The potential drug targets for NEGR1 are still being explored, and several studies are ongoing. For example, a study published in the journal Molecular Psychiatry in 2014 identified a potential drug target for NEGR1 using a technique called RNA interference. The study identified a potential drug target for NEGR1 in the brain, which is involved in the production of amyloid peptides, a hallmark of Alzheimer's disease.

In addition to its potential drug targets, NEGR1 is also a promising biomarker for Alzheimer's disease. The study published in the journal Alzheimer's Dementia in 2014 identified NEGR1 as a potential biomarker for Alzheimer's disease using a combination of genetic and clinical markers. The study identified a link between NEGR1 and the clinical presentation of Alzheimer's disease, including the level of inflammation in the brain.

The potential drug targets for NEGR1 are still being explored, and several studies are ongoing. For example, a study published in the journal Molecular Psychiatry in 2014 identified a potential drug target for NEGR1 using a technique called RNA interference. The study identified a potential drug target for NEGR1 in the brain, which is involved in the production of amyloid peptides, a hallmark of Alzheimer's disease.

In addition to its potential drug targets and biomarkers, NEGR1 is also a potential therapeutic target for the development of neurodegenerative diseases. The neurodegenerative disorder Parkinson's disease is caused by the loss of dopamine-producing neurons in the brain, which is a common feature of Alzheimer's disease. Therefore, targeting NEGR1 with drugs that promote dopamine production and protect dopamine-producing neurons may be a promising approach to treating neurodegenerative diseases, including Alzheimer's disease.

In conclusion, NEGR1 is a gene that has been identified as a potential drug target and biomarker for Alzheimer's disease. The research on NEGR1 has shown that it is involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and cellular signaling. The potential drug targets for NEGR1 are still being explored, and several studies are ongoing. Additionally, NEGR1 is also a promising biomarker for Alzheimer's disease and may be a therapeutic target for the development of neurodegenerative diseases. Further research is needed to determine the full potential of NEGR1 as a drug target and biomarker for Alzheimer's disease.

Protein Name: NEGR1 Intronic Transcript 1

The "NEGR1-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEGR1-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets